MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$97K
Free Cash flow
-$23,453K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of avai...
Stock-based compensation
Change in fair value of continge...
Others
Negative Cash Flow Breakdown
Net (loss) income
Accounts receivable, net
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net (loss) income
-19,032
-16,619
-15,948
7,985
Stock-based compensation
10,226
6,455
6,972
4,318
Interest on liability for sale of future royalties
506
2,565
3,885
3,512
Sold portion of royalty revenue
3,237
3,275
3,356
3,332
Write-off of inventory
1,372
1,075
2,062
3,277
Noncash lease expense of right-of-use assets
444
532
-603
740
Depreciation and amortization
6,398
6,382
6,030
2,061
(gain) loss on foreign currency transactions
486
1,318
3
120
Impairment loss on available-for-sale investment
-
-
0
-6,409
Net accretion of investments
-181
-271
-402
-567
Change in fair value of contingent liability
-
-2,777
1,029
-
Change in fair value of contingent consideration liability
-7,769
-
-
-
Amortization of debt discount and issuance costs
414
452
478
158
Loss on settlement of debt
0
-917
-
-
Other, net
-1
62
-155
-
Change in deferred tax liability
-
-
-4,969
-
Accounts receivable, net
15,070
-10,290
-817
-9,759
Inventory
-3,375
14,928
-797
1,758
Prepaid expenses and other current assets
6,960
-6,557
-2,328
6,989
Other assets
-4,448
2,416
383
1
Accounts payable
-5,118
7,110
-17,188
-2,988
Accrued expenses and other current liabilities
2,831
-5,771
13,350
-761
Deferred revenue
-2,488
-4,878
-3,009
1,891
Operating lease liabilities
-806
-939
0
46
Net cash (used in) provided by operating activities
-18,371
-5,365
-7,958
23,640
Proceeds from maturities of available-for-sale securities
22,991
30,906
71,496
42,020
Acquisition of scpharma, net of cash acquired
-
-
347,742
-
Issuance of note receivable
-
-
0
10,000
Purchase of available-for-sale securities
0
10,301
13,723
55,953
Purchase of property and equipment
5,082
1,880
1,994
1,125
Net cash provided by investing activities
17,909
18,725
-291,963
-25,058
Proceeds from term loan
-
-
250,000
75,000
Payment of loan issuance costs
-
-
4,919
2,347
Principal payments on senior convertible notes
0
35,502
-
-
Net proceeds related to issuance of common stock associated with restricted stock units and stock options
823
-105
-1,874
743
Principal payments on financing liability
260
279
196
154
Proceeds from market price stock purchase plan and employee stock purchase plan
1,912
-
654
50
Milestone right agreement payment
-
-
0
639
Proceeds from market price stock purchase plan
-
270
-
-
Net cash used in financing activities
559
-35,406
247,413
71,806
Net (decrease) increase in cash, cash equivalents and restricted cash
97
-22,046
-52,508
70,388
Cash, cash equivalents and restricted cash, beginning of period
53,581
75,627
128,135
47,076
Cash, cash equivalents and restricted cash, end of period
53,678
53,581
75,627
128,135
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
of...
$22,991K
(-77.41%↓ Y/Y)
Proceeds from market
price stock purchase...
$1,912K
(48.45%↑ Y/Y)
Net cash provided by
investing activities
$17,909K
(46.58%↑ Y/Y)
Net cash used in
financing activities
$559K
(113.57%↑ Y/Y)
Canceled cashflow
$5,082K
Canceled cashflow
$1,353K
Net (decrease)
increase in cash, cash...
$97K
(-99.09%↓ Y/Y)
Canceled cashflow
$18,371K
Purchase of property and
equipment
$5,082K
(251.21%↑ Y/Y)
Stock-based compensation
$10,226K
(-20.76%↓ Y/Y)
Change in fair value of
contingent consideration...
-$7,769K
Depreciation and
amortization
$6,398K
(52.59%↑ Y/Y)
Other assets
-$4,448K
(-391.67%↓ Y/Y)
Inventory
-$3,375K
(-159.60%↓ Y/Y)
Accrued expenses and
other current...
$2,831K
(130.33%↑ Y/Y)
Write-off of inventory
$1,372K
(-72.87%↓ Y/Y)
Interest on liability for
sale of future...
$506K
(-92.82%↓ Y/Y)
Noncash lease expense of
right-of-use assets
$444K
(-58.70%↓ Y/Y)
Amortization of debt discount
and issuance costs
$414K
(89.91%↑ Y/Y)
Other, net
-$1K
Net proceeds
related to issuance of...
$823K
(-81.27%↓ Y/Y)
something is missing
-$270K
Principal payments on
financing liability
$260K
(-30.85%↓ Y/Y)
Net cash (used in)
provided by operating...
-$18,371K
(-813.99%↓ Y/Y)
Canceled cashflow
$37,784K
Net (loss) income
-$19,032K
(-237.65%↓ Y/Y)
Accounts receivable, net
$15,070K
(-1.75%↓ Y/Y)
Prepaid expenses and
other current assets
$6,960K
(29.58%↑ Y/Y)
Accounts payable
-$5,118K
(-247.71%↓ Y/Y)
Sold portion of
royalty revenue
$3,237K
(-47.13%↓ Y/Y)
something is missing
-$2,777K
Deferred revenue
-$2,488K
(65.16%↑ Y/Y)
Operating lease
liabilities
-$806K
(12.30%↑ Y/Y)
(gain) loss on foreign
currency transactions
$486K
(106.17%↑ Y/Y)
Net accretion of
investments
-$181K
(89.21%↑ Y/Y)
Buy us a coffee
MANNKIND CORP (MNKD)
MANNKIND CORP (MNKD)